Targeted Oncology2d
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Targeted Oncology12d
Bevacizumab Benefits in CRC Persist for Two Years After Initiation
A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric cancer. Read more here.
Monthly Prescribing Reference3d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
oncnursingnews1d
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
WPXI16d
Overview of common vision problems and medications
Photodynamic therapy: Often used in conjunction with Lucentis or Avastin, photodynamic therapy uses the drug verteporfin (Visudyne) to treat wet AMD. About 40% to 60% of people with wet macular ...